Sato et al. Radiology 2008;247:507-515【1】
mCRC Radioembolization
1. Sato KT1, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology. 2008 May;247(2):507-15. doi:0.1148/radiol.2472062029. Epub 2008 Mar 18.
2. Benson AB 3rd1, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013 Oct;49(15):3122-30. doi: 10.1016/j.ejca.2013.05.012. Epub 2013 Jun 15.
Patients with liver metastases can be safely treated with 90Y microspheres. This study is the first to demonstrate technical and dose reproducibility of 90Y glass microspheres between centers in a prospective setting. Based on these promising data, three international, multicenter, randomised phase III studies in colorectal and hepatocellular carcinoma have been initiated.
Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, Newman S, Talamonti M, Omary RA, Benson A 3rd, Salem R. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009 May 1;115(9):1849-58. doi: 10.1002 /cncr.24224.
Y90 liver therapy appears to provide sustained disease stabilization with acceptable toxicity. Asymptomatic patients with preserved liver function at the time of Y90 appeared to benefit most from treatment. |